ViraTherapeutics
Latest round
- Series A
Last raised
- Jun 2015
Total raised
- $4M
Investors
- 3
About ViraTherapeutics
Founded in 2013 and headquartered in Innsbruck, Austria, ViraTherapeutics GmbH operates in the biotechnology sector, concentrating on the development of immunotherapy solutions. The company has not undergone any known structural changes since its inception. ViraTherapeutics was acquired by Boehringer Ingelheim International GmbH in September 2018 for EUR 210 million. The CEO of the company is Knut Elbers, who has a history of operational leadership in the biotechnology field.ViraTherapeutics GmbH specializes in the development of innovative immunotherapy drugs utilizing a patented modified version of the Vesicular Stomatitis Virus (VSV-GP). These therapeutic agents are engineered to selectively target and destroy cancer cells while sparing healthy tissue. ViraTherapeutics is currently engaged in preclinical safety and efficacy studies, with plans to initiate clinical trials targeting various cancer types.The revenue model of ViraTherapeutics is centered around partnerships and collaborations with research institutions and pharmaceutical companies interested in developing and commercializing innovative cancer therapies. These collaborations typically involve milestone payments associated with the progression of clinical trials, as well as licensing agreements for their proprietary technologies.ViraTherapeutics plans to leverage its recent acquisition by Boehringer Ingelheim to enhance its development capabilities and accelerate the launch of new immunotherapy products. The company is focused on expanding its clinical trials for various cancer types with a targeted launch timeline in the coming years.
Who invested in ViraTherapeutics
3 investors across 1 round
See all investors in ViraTherapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Jun 24, 2015
Amount
$4M
Investors
Questions about ViraTherapeutics
Who invested in ViraTherapeutics?
ViraTherapeutics has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has ViraTherapeutics raised?
ViraTherapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did ViraTherapeutics last raise money?
ViraTherapeutics's most recent round on record is a Series A, in Jun 2015.
What does ViraTherapeutics do?
Founded in 2013 and headquartered in Innsbruck, Austria, ViraTherapeutics GmbH operates in the biotechnology sector, concentrating on the development of immunotherapy solutions.
Where is ViraTherapeutics headquartered?
ViraTherapeutics is headquartered in Innsbruck, Austria.
Which VCs invest in companies like ViraTherapeutics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at ViraTherapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like ViraTherapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.